NCT07457580Recruiting
Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)
A Real-World Retrospective Observational Study Characterizing Patients With Stage 2 Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)
Source: ClinicalTrials.gov · Last updated 26 Aug 2026
Brief summary (registry, in English)
This study is a multi-country, multi-center retrospective observational cohort study based on secondary data collected via chart review, with the aim of describing patient characteristics (including relevant comorbidities), monitoring and treatment practices related to Type 1 diabetes mellitus (T1D) progression, and time to T1D progression in participants who received teplizumab as part of Managed Access Programs (MAPs). This study design was chosen in order to gain rapid insight into the current use of teplizumab in clinical practice and the characteristics of patients who received the treatment.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 12 Feb 2026
- Start date
- 16 Mar 2026
- Primary completion date
- 30 Nov 2026
- Lead sponsor
- Sanofi
- Diseases
- Type 1 diabetes, Type 2 diabetes
- NCT number
- NCT07457580
What you commit to
- Study type: Observational
- Planned participants: 60
- From 16 Mar 2026 to the primary completion date, 30 Nov 2026
- 14 sites in 6 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Participation in an interventional clinical study on the index date. Participation in an interventional clinical study is defined as initiating the product/procedure or control under investigation. An interventional clinical study is a study that requires deviation from standard clinical practice by following a study protocol.
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Who the study is looking for
- Patient written or electronic informed consent or assent (for patients \< 18 years old) according to local regulations or appropriate informed consent waivers prior to any study related activity.
- Patient received ≥ 1 day of teplizumab treatment as part of MAPs.
Sex: All · Does not accept healthy volunteers
Sites (14)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Leuven | Belgium | Recruiting |
| - Coordinator of this site? Confirm its status | Frankfurt | Germany | Recruiting |
| - Coordinator of this site? Confirm its status | Hanover | Germany | Recruiting |
| - Coordinator of this site? Confirm its status | Madrid | Spain | Recruiting |
| - Coordinator of this site? Confirm its status | Madrid | Spain | Recruiting |
| - Coordinator of this site? Confirm its status | Zaragoza | Spain | Recruiting |
| - Coordinator of this site? Confirm its status | Bron | France | Recruiting |
| - Coordinator of this site? Confirm its status | Paris | France | Recruiting |
| - Coordinator of this site? Confirm its status | Paris | France | Recruiting |
| - Coordinator of this site? Confirm its status | Birmingham | United Kingdom | Recruiting |
| - Coordinator of this site? Confirm its status | London | United Kingdom | Recruiting |
| - Coordinator of this site? Confirm its status | Ancona | Italy | Recruiting |
| - Coordinator of this site? Confirm its status | Palermo | Italy | Recruiting |
| - Coordinator of this site? Confirm its status | Verona | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.